查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601610

神經基因組學市場規模、佔有率、預測和趨勢分析：按產品（NGS [試劑盒、系統]、PCR、微陣列、軟體）、按應用（研究、臨床）和最終用戶劃分 - 到 2031 年的全球預測

Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits, Systems], PCR, Microarrays, Software) Application (Research, Clinical) End User - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 250 Pages | 商品交期: 最快1-2個工作天內

價格

神經基因體學市場預計到 2031 年將達到 46.8 億美元，2024 年至 2031 年複合年增長率為 16.6%。

經過廣泛的二次和初步研究以及對市場情景的詳細分析，本報告對關鍵行業推動因素、阻礙因素、機會和挑戰進行了分析。

神經基因組學市場的成長是由定序成本下降、神經系統疾病盛行率增加、先進定序技術在疾病診斷和精準醫療中的廣泛使用、藥品研發成本增加以及基因定序法規和報銷方案所推動的。政府增加醫療保健支出、增加對研究活動的資助、增加對神經系統疾病的早期檢測和預防的需求、神經基因組學產品的技術進步以及促進測序在臨床和研究中的應用是這一舉措的驅動力。然而，神經基因組學產品的高價格、精準醫學識別積極可行突變的可能性較低，以及與基於序列的診斷相關的倫理和法律問題正在阻礙該市場的成長。

此外，擴大採用標靶治療、新興經濟體以及對神經系統疾病的認識不斷增強，預計將為市場利益相關者提供成長機會。然而，動態的監管環境、中小型實驗室的專業知識和測序能力有限、測序專家的短缺以及測序設置所需的高資本投資是影響神經基因組學市場成長的主要挑戰。

本報告包​​括基於對四年期間（2021-2024 年）主要市場參與者的產品組合、區域影響力和關鍵策略發展的廣泛評估所得出的競爭格局。參與神經基因體學市場的主要公司有Illumina, Inc.（美國）、Thermo Fisher Scientific Inc.（美國）、F. Hoffmann-La Roche Ltd（瑞士）、QIAGEN N.V.（荷蘭）、Agilent Technologies, Inc.（美國) )、Revvity, Inc.（美國）、Pacific Biosciences of California Inc.（美國）、Danaher Corporation（美國）、Oxford Nanopore Technologies Plc.（英國）和MGI Tech Co., Ltd.（中國）。

在本報告研究的產品中，次世代定序 (NGS) 領域預計將在 2024 年佔據神經基因組市場的最大佔有率，達到 63.9%。此細分市場的大部分佔有率歸因於最終用戶對下一代定序解決方案的需求不斷增長、神經學研究中樣品製備耗材的重複使用、NGS 的可承受性不斷提高以及基因組研究的增長。

在本報告調查的應用中，研究領域預計將在 2024 年佔據神經基因組學市場的很大佔有率，達到 61.6%。該細分市場的很大一部分是由於神經基因組學中使用的先進解決方案的成本下降、製藥和生物技術公司加強研發力度以推進精準醫學和藥物發現而推動的，這是由於使用資訊學解決方案來發現藥理學標靶。

在本報告調查的最終用戶中，製藥和生物技術領域預計將在 2024 年佔據神經基因組學市場的最大佔有率，達到 44.6%。該細分市場的巨大市場佔有率是由製藥和生物技術公司研發支出增加以及神經系統疾病患病率上升推動的，這推動了製藥和生物技術公司採用先進產品，這是因為他們對此提供支持。

調查範圍：

神經基因組學市場評估：透過產品

  • 次世代定序儀
    • 系統
    • 試劑盒和試劑
  • DNA 萃取和擴增試劑盒及試劑
  • 文庫製備及標靶富集試劑盒及試劑
  • 品質控制套件和試劑
    • 其他試劑盒和試劑
  • 聚合酶鍊式反應 (PCR)
    • 系統
    • 試劑盒和試劑
  • 微陣列晶片
    • 閱讀器和掃瞄儀
    • 試劑盒和試劑
  • DNA 和 RNA 微陣列試劑盒和試劑
  • 蛋白質微陣列試劑盒和試劑
  • 組織微陣列試劑盒和試劑
  • 軟體與服務

神經基因體學市場評估：依應用分類

  • 研究用途
    • 目標識別
    • 功能研究
    • 突變體搜索
    • 轉錄因子結合分析
  • 臨床應用

神經基因組學市場評估：按最終用戶劃分

  • 製藥和生技公司
  • 學術/研究機構
  • 醫院/診斷實驗室

神經基因組學市場評估：按地區

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 西班牙
    • 其他歐洲 (RoE)
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區 (RoAPAC)
  • 拉丁美洲
  • 中東/非洲

目錄

第一章簡介

第二章研究方法

第 3 章執行摘要

第 4 章市場洞察

  • 摘要
  • 影響市場成長的因素
    • 市場動態影響分析
    • 因素分析
  • 價格分析
  • 技術趨勢
    • 便攜式定序技術的發展
  • 監理分析
    • 神經基因體學設備/消耗品
      • 北美
        • 美國
        • 加拿大
      • 歐洲
      • 亞太地區
        • 中國
        • 日本
        • 印度
      • 拉丁美洲
      • 中東
    • 神經基因體學軟體
  • 波特五力分析

第 5 章神經基因體學市場評估：透過產品

  • 摘要
  • 次世代定序儀 (NGS)
    • 試劑盒/試劑
      • 文庫製備及標靶富集試劑盒及試劑
      • DNA 萃取和擴增試劑盒及試劑
      • 品質控制套件和試劑
      • 其他試劑盒和試劑
    • 系統
  • 聚合酶鍊式反應 (PCR)
    • 試劑盒和試劑
    • 系統
  • 微陣列晶片
    • 試劑盒和試劑
      • DNA 和 RNA 微陣列試劑盒和試劑
      • 蛋白質微陣列試劑盒和試劑
      • 組織微陣列試劑盒和試劑
    • 閱讀器和掃瞄儀
  • 軟體與服務

第 6 章神經基因體學市場評估：依應用

  • 摘要
  • 研究用途
    • 目標識別
    • 功能研究
    • 突變體搜索
    • 轉錄因子結合分析
  • 臨床應用

第 7 章神經基因體學市場評估：最終使用者

  • 摘要
  • 製藥和生技公司
  • 學術/研究機構
  • 醫院/診斷實驗室

第 8 章神經基因體學市場評估：按地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲 (RoE)
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區 (RoAPAC)
  • 拉丁美洲
  • 中東/非洲

第9章競爭分析

  • 摘要
  • 主要成長策略
  • 競爭基準測試
  • 競爭對手儀表板
    • 行業領導者
    • 市場差異化因素
    • 領先企業
    • 新興公司
  • 市佔率分析（2023 年）
    • Illumina, Inc.（U.S.）
    • Thermo Fisher Scientific Inc.（U.S.）
    • F. Hoffmann-La Roche Ltd（Switzerland）

第 10 章公司簡介（業務概覽、財務概覽、產品組合、策略發展、SWOT 分析*）

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • MGI Tech Co., Ltd.
  • QIAGEN N.V.
  • Revvity, Inc.
  • Pacific Biosciences of California Inc.
  • Danaher Corporation
  • Oxford Nanopore Technologies Plc.

（註：*我們將提供前 5 名公司的 SWOT 分析。）

第11章附錄

Product Code: MRHC - 1041336

Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays {Protein, DNA, RNA, Tissue}, Software), Application (Research, Clinical), End User-Global Forecast to 2031

The neurogenomics market is projected to reach $4.68 billion by 2031 at a CAGR of 16.6% from 2024 to 2031.

Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report provides an analysis of key industry drivers, restraints, opportunities, and challenges.

The growth of the neurogenomics market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the growing utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of neurological disorders, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high prices of neurogenomics products, the low chances of identifying positive, actionable mutations for precision medicine, and ethical & legal issues related to sequencing-based diagnosis are factors restraining the growth of this market.

Furthermore, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to generate growth opportunities for market stakeholders. However, the dynamic regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the shortage of sequencing professionals, and the high capital investments required for sequencing setups are major challenges impacting the growth of the neurogenomics market.

The report includes a competitive landscape based on an extensive assessment of the product portfolios, geographic presence, and key strategic developments of leading market players during the four years (2021-2024). The key players operating in the neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).

Among the offerings studied in this report, in 2024, the Next-generation Sequencing (NGS) segment is expected to account for the largest share of 63.9% of the neurogenomics market. The large share of this segment is attributed to the rising demand for next-generation sequencing solutions from end users, the recurring use of sample preparation consumables in neurological research, the increasing affordability of NGS, and the growth in genomic studies.

Among the applications studied in this report, in 2024, the research segment is expected to account for the larger share of 61.6% of the neurogenomics market. The large share of this segment is attributed to the decreasing costs of advanced solutions used in neurogenomics, increasing R&D efforts of pharmaceutical and biotechnology companies for advancing precision medicine & drug discovery, and the use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.

Among the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of 44.6% of the neurogenomics market. The large market share of this segment is attributed to pharmaceutical & biotechnology companies' increasing R&D spending and the rising incidence of neurological diseases, which drives the adoption of advanced products among pharmaceutical & biotechnology companies.

Scope of the Report:

Neurogenomics Market Assessment-by Offering

  • Next-generation Sequencing
    • Systems
    • Kits & Reagents
  • DNA Extraction & Amplification Kits & Reagents
  • Library Preparation & Target Enrichment Kits & Reagents
  • Quality Control Kits & Reagents
    • Other Kits & Reagents
  • Polymerase Chain Reaction (PCR)
    • Systems
    • Kits & Reagents
  • Microarray
    • Readers & Scanners
    • Kits & Reagents
  • DNA & RNA Microarray Kits & Reagents
  • Protein Microarray Kits & Reagents
  • Tissue Microarray Kits & Reagents
  • Software & Services

Neurogenomics Market Assessment-by Application

  • Research Applications
    • Target Identification
    • Functional Studies
    • Variant Discovery
    • Transcription Factor Binding Analysis
  • Clinical Applications

Neurogenomics Market Assessment-by End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Hospitals & Diagnostic Laboratories

Neurogenomics Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition and Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitation
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection and Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing and Forecast
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Market Share Analysis
    • 2.3.3. Growth Forecast Approach
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Impact Analysis of Market Dynamics
    • 4.2.2. Factor Analysis
  • 4.3. Pricing Analysis
  • 4.4. Technology Trends
    • 4.4.1. Development of Portable Sequencing Technologies
  • 4.5. Regulatory Analysis
    • 4.5.1. Neurogenomics Instruments & Consumables
      • 4.5.1.1. North America
        • 4.5.1.1.1. U.S.
        • 4.5.1.1.2. Canada
      • 4.5.1.2. Europe
      • 4.5.1.3. Asia-Pacific
        • 4.5.1.3.1. China
        • 4.5.1.3.2. Japan
        • 4.5.1.3.3. India
      • 4.5.1.4. Latin America
      • 4.5.1.5. Middle East
    • 4.5.2. Neurogenomics Software
  • 4.6. Porter's Five Forces Analysis

5. Neurogenomics Market Assessment-by Offering

  • 5.1. Overview
  • 5.2. Next-generation Sequencing (NGS)
    • 5.2.1. Kits & Reagents
      • 5.2.1.1. Library Preparation & Target Enrichment Kits & Reagents
      • 5.2.1.2. DNA Extraction and Amplification Kits & Reagents
      • 5.2.1.3. Quality Control Kits & Reagents
      • 5.2.1.4. Other Kits & Reagents
    • 5.2.2. Systems
  • 5.3. Polymerase Chain Reaction (PCR)
    • 5.3.1. Kits & Reagents
    • 5.3.2. Systems
  • 5.4. Microarray
    • 5.4.1. Kits & Reagents
      • 5.4.1.1. DNA & RNA Microarray Kits & Reagents
      • 5.4.1.2. Protein Microarray Kits & Reagents
      • 5.4.1.3. Tissue Microarray Kits & Reagents
    • 5.4.2. Readers & Scanners
  • 5.5. Software & Services

6. Neurogenomics Market Assessment-by Application

  • 6.1. Overview
  • 6.2. Research Applications
    • 6.2.1. Target Identification
    • 6.2.2. Functional Studies
    • 6.2.3. Variant Discovery
    • 6.2.4. Transcription Factor Binding Analysis
  • 6.3. Clinical Applications

7. Neurogenomics Market Assessment-by End User

  • 7.1. Overview
  • 7.2. Pharmaceutical & Biotechnology Companies
  • 7.3. Academic & Research Institutes
  • 7.4. Hospitals & Diagnostic Laboratories

8. Neurogenomics Market Assessment-by Geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. France
    • 8.3.3. U.K.
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe (RoE)
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Rest of Asia-Pacific (RoAPAC)
  • 8.5. Latin America
  • 8.6. Middle East & Africa

9. Competition Analysis

  • 9.1. Overview
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Benchmarking
  • 9.4. Competitive Dashboard
    • 9.4.1. Industry Leaders
    • 9.4.2. Market Differentiators
    • 9.4.3. Vanguards
    • 9.4.4. Emerging Companies
  • 9.5. Market Share Analysis (2023)
    • 9.5.1. Illumina, Inc. (U.S.)
    • 9.5.2. Thermo Fisher Scientific Inc. (U.S.)
    • 9.5.3. F. Hoffmann-La Roche Ltd (Switzerland)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

  • 10.1. Illumina, Inc.
  • 10.2. Thermo Fisher Scientific Inc.
  • 10.3. F. Hoffmann-La Roche Ltd
  • 10.4. Agilent Technologies, Inc.
  • 10.5. MGI Tech Co., Ltd.
  • 10.6. QIAGEN N.V.
  • 10.7. Revvity, Inc.
  • 10.8. Pacific Biosciences of California Inc.
  • 10.9. Danaher Corporation
  • 10.10. Oxford Nanopore Technologies Plc.

(Note: *SWOT Analysis of the top 5 companies will be provided)

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports

LIST OF TABLES

  • Table 1 Global Estimated Number of New Brain & Central Nervous System Cancer Cases, by Region, 2020 Vs. 2045
  • Table 2 Sequencing Kits & Reagents/Consumables: Pricing
  • Table 3 Sequencing Instruments: Product Description & Pricing
  • Table 4 PCR Consumables & Instruments: Pricing
  • Table 5 Portable Sequencers VS. Benchtop Sequencers: Key Differences
  • Table 6 Regulatory Authorities Governing In Vitro Diagnostics & Neurogenomics Solutions, by Country/Region
  • Table 7 Neurogenomics Software: Standards and Compliance Guidelines
  • Table 8 Global Neurogenomics Market, by offering, 2022-2031 (USD Million)
  • Table 9 Global Next-generation Sequencing (NGS) Market for Neurogenomics, by Product, 2022-2031 (USD Million)
  • Table 10 Global Next-generation Sequencing (NGS) Market for Neurogenomics, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Global Next-generation Sequencing (NGS) Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 12 Global Next-generation Sequencing (NGS) Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Global Library Preparation and Target Enrichment Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global DNA Extraction & Amplification Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Global Quality Control Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 16 Global Other Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global NGS Systems Market, by Country/Region, 2022-2031 (USD Million)
  • Table 18 Global Polymerase Chain Reaction (PCR) Market for Neurogenomics, by Type, 2022-2031 (USD Million)
  • Table 19 Global Polymerase Chain Reaction (PCR) Market for Neurogenomics, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global PCR Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Global PCR Systems Market, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global Microarrays Market for Neurogenomics, by Type, 2022-2031 (USD Million)
  • Table 23 Global Microarrays Market for Neurogenomics, by Country/Region, 2022-2031 (USD Million)
  • Table 24 Global Microarrays Kits & Reagents Market, by Type, 2022-2031 (USD MILLION)
  • Table 25 Global Microarrays Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Global DNA & RNA Microarray Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Global Protein Microarray Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 28 Global Tissue Microarray Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Microarray Readers & Scanners Market, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Neurogenomics Software & Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 32 Global Neurogenomics Market for Research Applications, by Type, 2022-2031 (USD Million)
  • Table 33 Global Neurogenomics Market for Target Identification, 2022-2031 (USD Million)
  • Table 34 Global Neurogenomics Market for Functional Studies, 2022-2031 (USD MILLION)
  • Table 35 Global Neurogenomics Market for Variant Discovery, 2022-2031 (USD MILLION)
  • Table 36 Global Neurogenomics Market for Transcription Factor Binding Analysis, 2022-2031 (USD MILLION)
  • Table 37 Global Neurogenomics Market for Clinical Applications, 2022-2031 (USD MILLION)
  • Table 38 Global Neurogenomics Market, By End User, 2022-2031 (USD MILLION)
  • Table 39 Pharmaceutical Spending in Major Countries
  • Table 40 Global Neurogenomics Market for Pharmaceutical & Biotechnology Companies, 2022-2031 (USD Million)
  • Table 41 Global Neurogenomics Market for Academic & Research Institutes, 2022-2031 (USD Million)
  • Table 42 Global Neurogenomics Market for Hospitals & Diagnostic Laboratories, 2022-2031 (USD MILLION)
  • Table 43 Global Neurogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 44 North America: Neurogenomics Market, by Country, 2022-2031 (USD Million)
  • Table 45 North America: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 46 North America: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 47 North America: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 48 North America: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 49 North America: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 50 North America: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 51 North America: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 52 North America: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 53 North America: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 54 U.S.: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 55 U.S.: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 56 U.S.: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 57 U.S.: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 58 U.S.: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 59 U.S.: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 60 U.S.: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 61 U.S.: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 62 U.S.: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 63 Canada: Neurogenomics Market, by offering, 2022-2031 (USD Million)
  • Table 64 Canada: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 65 Canada: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 66 Canada: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 67 Canada: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 68 Canada: Neurogenomics Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 69 Canada: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 70 Canada: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 71 Canada: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 72 Europe: Neurogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 73 Europe: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 74 Europe: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 75 Europe: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 76 Europe: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 77 Europe: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 78 Europe: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 79 Europe: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 80 Europe: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 81 Europe: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 82 Germany: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 83 Germany: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 84 Germany: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 85 Germany: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 86 Germany: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 87 Germany: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 88 Germany: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 89 Germany: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 90 Germany: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 91 France: Deaths due to Neuropsychiatric Conditions, by Sex and Age Group (2020)
  • Table 92 France: Neurogenomics Market, by offering, 2022-2031 (USD Million)
  • Table 93 France: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 94 France: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 95 France: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 96 France: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 97 France: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 98 France: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 99 France: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 100 France: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 101 Emergency In-Patient Hospital Admissions With a Mention Of Neurological Emergency Codes in England Among Adults Aged 18 Years and Over (2019-2020)
  • Table 102 Number of Deaths Registered due to Dementia and Alzheimer's Disease in Wales and in Regions of England (2019)
  • Table 103 U.K.: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 104 U.K.: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 105 U.K.: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 106 U.K.: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 107 U.K.: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 108 U.K.: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 109 U.K.: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 110 U.K.: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 111 U.K.: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 112 Italy: Deaths due to Neuropsychiatric Conditions, by Sex and Age Group (2020)
  • Table 113 Italy: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 114 Italy: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 115 Italy: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 116 Italy: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 117 Italy: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 118 Italy: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 119 Italy: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 120 Italy: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 121 Italy: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 122 Spain: Deaths Due to Neuropsychiatric Conditions, by Sex and Age Group (2021)
  • Table 123 Spain: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 124 Spain: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 125 Spain: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 126 Spain: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 127 Spain: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 128 Spain: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 129 Spain: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 130 Spain: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 131 Spain: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 132 RoE: Estimated Number Of New Brain And Central Nervous System Cancer Cases, by Country (2022 Vs. 2045)
  • Table 133 Rest of Europe: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 134 Rest of Europe: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 135 Rest of Europe: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 136 Rest of Europe: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 137 Rest of Europe: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 138 Rest of Europe: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 139 Rest of Europe: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 140 Rest of Europe: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 141 Rest of Europe: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 142 Asia-Pacific: Neurogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 143 Asia-Pacific: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 144 Asia-Pacific: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 145 Asia-Pacific: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 146 Asia-Pacific: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 147 Asia-Pacific: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 148 Asia-Pacific: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 149 Asia-Pacific: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 150 Asia-Pacific: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 151 Asia-Pacific: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 152 China: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 153 China: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 154 China: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 155 China: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 156 China: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 157 China: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 158 China: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 159 China: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 160 China: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 161 Japan: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 162 Japan: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 163 Japan: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 164 Japan: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 165 Japan: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 166 Japan: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 167 Japan: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 168 Japan: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 169 Japan: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 170 India: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 171 India: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 172 India: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 173 India: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 174 India: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 175 India: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 176 India: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 177 India: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 178 India: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 179 Rest of Asia-Pacific: Estimated Number of New Brain and Central Nervous System Cancer Cases, By Country (2022 VS. 2040)
  • Table 180 Rest of Asia-Pacific: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 181 Rest of Asia-Pacific: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 182 Rest of Asia-Pacific: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 183 Rest of Asia-Pacific: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 184 Rest of Asia-Pacific: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 185 Rest of Asia-Pacific: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 186 Rest of Asia-Pacific: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 187 Rest of Asia-Pacific: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 188 Rest of Asia-Pacific: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 189 Latin America: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 190 Latin America: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 191 Latin America: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 192 Latin America: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 193 Latin America: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 194 Latin America: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 195 Latin America: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 196 Latin America: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 197 Latin America: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 198 Middle East & Africa: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 199 Middle East & Africa: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 200 Middle East & Africa: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 201 Middle East & Africa: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
  • Table 202 Middle East & Africa: Microarrays Market, by Type, 2022-2031 (USD Million)
  • Table 203 Middle East & Africa: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
  • Table 204 Middle East & Africa: Neurogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 205 Middle East & Africa: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
  • Table 206 Middle East & Africa: Neurogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 207 Recent Developments, by Company, 2021-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referenced for This Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Sizing and Growth Forecast Approach
  • Figure 7 Global Neurogenomics Market, By Offering, 2024 VS. 2031 (USD Million)
  • Figure 8 Global Neurogenomics Market, By Application, 2024 VS. 2031 (USD Million)
  • Figure 9 Global Neurogenomics Market, By End User, 2024 VS. 2031 (USD Million)
  • Figure 10 Global Neurogenomics Market: Impact Analysis of Market Drivers, Restraints, Opportunities, and Challenges (2024-2031)
  • Figure 11 Genome Sequencing Costs, 2016-2024 (USD/Genome)
  • Figure 12 Global Pharmaceutical R&D Expenditure, 2012-2026 (USD Billion)
  • Figure 13 U.S.: Percentage Of Personalized Medicine Approvals Among Total FDA Approvals, 2015-2022 (%)
  • Figure 14 U.S.: Percentage Distribution Of Older Adults With Alzheimer's Dementia, By Age Group, 2024
  • Figure 15 Deaths due to Neuropsychiatric Conditions, By Country, 2020
  • Figure 16 Deaths due to Parkinson's Disease, By Country, 2021
  • Figure 17 Deaths due to Alzheimer's And Other Dementias, By Country, 2021
  • Figure 18 USFDA Regulatory Pathways for IVD Kits
  • Figure 19 Eu Regulatory Pathway - IVDR 2017/746
  • Figure 20 China: Medical Device Classification And Premarket Requirements for Neurogenomics Instruments
  • Figure 21 Porter's Five Forces Analysis
  • Figure 22 Global Neurogenomics Market, By Offering, 2024 VS. 2031 (USD Million)
  • Figure 23 Global Neurogenomics Market, By Application, 2024 VS. 2031 (USD Million)
  • Figure 24 Global Neurogenomics Market, By End User, 2024 VS. 2031 (USD Million)
  • Figure 25 Global Pharmaceutical R&D Expenditure, 2014-2028 (USD Billion)
  • Figure 26 Global Neurogenomics Market, By Region, 2024 Vs. 2031 (USD Million)
  • Figure 27 North America: Per Capita Healthcare Expenditure (2017-2022)
  • Figure 28 North America: Neurogenomics Market Snapshot
  • Figure 29 Europe: Pharmaceutical R&D Expenditure Annual Growth Rate (%)
  • Figure 30 Europe: Neurogenomics Market Snapshot
  • Figure 31 Italy: Number Of Biotechnology And Biotechnology R&D-Dedicated Firms (2014-2022)
  • Figure 32 Spain: Pharmaceutical R&D Expenditure, 2018-2022 (USD Million)
  • Figure 33 Asia-Pacific: Neurogenomics Market Snapshot
  • Figure 34 Japan: Pharmaceutical Industry R&D Expenditure, 2017-2022 (USD Million)
  • Figure 35 Number of Active Life Science Companies in Israel (2017-2022)
  • Figure 36 Israel: Total Number of Life Science Industries, by Sub-Sectors (2021)
  • Figure 37 Key Growth Strategies Adopted by Leading Players, 2021- 2024
  • Figure 38 Global Neurogenomics Market: Competitive Benchmarking by Offering
  • Figure 39 Global Neurogenomics Market: Competitive Benchmarking, by Region
  • Figure 40 Competitive Dashboard: Global Neurogenomics Market
  • Figure 41 Global Neurogenomics Market Share Analysis, by Key Players, 2023 (%)
  • Figure 42 Illumina, Inc.: Financial Snapshot (2023)
  • Figure 43 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
  • Figure 44 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2023)
  • Figure 45 Agilent Technologies, Inc.: Financial Snapshot (2023)
  • Figure 46 MGI Tech Co., Ltd.: Financial Snapshot (2023)
  • Figure 47 QIAGEN N.V: Financial Snapshot (2023)
  • Figure 48 Revvity, Inc.: Financial Snapshot (2023)
  • Figure 49 Pacific Biosciences Of California Inc.: Financial Snapshot (2023)
  • Figure 50 Danaher Corporation: Financial Snapshot (2023)
  • Figure 51 Oxford Nanopore Technologies Plc.: Financial Snapshot (2023)